Study Title
In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer
Study Details
Description:
This study aims to investigate the expression of FAP by phosphor imaging in invasive vulvar squamous cell carcinoma specimens. This in vitro study will include all consecutive tumour specimens stored both in optimal cutting temperature (OCT) compound and formalin-fixed paraffin-embedded (FFPE) from patients with a first diagnosis of vulvar squamous cell carcinoma who underwent surgery at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Sponsor:
Fondazione Italiana Linfomi - ETS
Contacts:
Angela Collarino, MD, PhDangela.collarino@policlinicogemell.it
0039 06 3015 6157
Government Study Link:
NCT06911801 - Click here to see study onClinicalTrials.gov
Drug Details
[18F]F-FAPI-74
Isotope(s):
- FLUORINE-18
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- FAP
